Ferroptosis Pathway in Neurodegeneration

Ferroptosis Pathway in Neurodegeneration

Introduction

Ferroptosis is an iron-dependent, lipid peroxidation-driven form of non-apoptotic cell death that has emerged as a critical mechanism in neurodegenerative diseases. Unlike apoptosis, necroptosis, or pyroptosis, ferroptosis is characterized by iron accumulation, lipid peroxidation, and glutathione depletion, leading to plasma membrane damage and cell death[@dixon2012]. This distinct cell death pathway was first formally described in 2012 by Dixon et al., but the conceptual foundation dates back to earlier observations of iron-mediated cell death in various disease contexts.

The name "ferroptosis" derives from the Greek word "ptosis" meaning "falling" or "death," combined with "ferro" referring to iron, the essential metal that drives the process. Unlike classical apoptosis which requires caspase activation and energy-dependent execution, ferroptosis represents a form of regulated necrosis that depends on iron-catalyzed lipid peroxidation[@stockwell2017].

In the context of neurodegeneration, ferroptosis has emerged as a key pathological mechanism contributing to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and multiple other neurodegenerative conditions. The recognition that neurons can die through ferroptosis rather than classical apoptosis has opened new therapeutic avenues for these currently incurable disorders.

Overview

Ferroptosis Pathway in Neurodegeneration

Introduction

Ferroptosis is an iron-dependent, lipid peroxidation-driven form of non-apoptotic cell death that has emerged as a critical mechanism in neurodegenerative diseases. Unlike apoptosis, necroptosis, or pyroptosis, ferroptosis is characterized by iron accumulation, lipid peroxidation, and glutathione depletion, leading to plasma membrane damage and cell death[@dixon2012]. This distinct cell death pathway was first formally described in 2012 by Dixon et al., but the conceptual foundation dates back to earlier observations of iron-mediated cell death in various disease contexts.

The name "ferroptosis" derives from the Greek word "ptosis" meaning "falling" or "death," combined with "ferro" referring to iron, the essential metal that drives the process. Unlike classical apoptosis which requires caspase activation and energy-dependent execution, ferroptosis represents a form of regulated necrosis that depends on iron-catalyzed lipid peroxidation[@stockwell2017].

In the context of neurodegeneration, ferroptosis has emerged as a key pathological mechanism contributing to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and multiple other neurodegenerative conditions. The recognition that neurons can die through ferroptosis rather than classical apoptosis has opened new therapeutic avenues for these currently incurable disorders.

Overview

Ferroptosis represents a unique form of cell death that is biochemically and morphologically distinct from other regulated cell death pathways. The key features that define ferroptosis include:

• Iron dependency: The process requires intracellular iron through the Fenton reaction
• Lipid peroxidation: Accumulation of peroxidated lipids, particularly polyunsaturated fatty acids (PUFAs)
• Glutathione depletion: Loss of the antioxidant glutathione impairs cellular defense
• GPX4 inactivation: Glutathione peroxidase 4 is the key enzymatic regulator
• Morphological changes: Small dense mitochondria with intact plasma membrane until late stages

The balance between ferroptosis inducers and defense systems determines cell fate. When the lipid peroxidation burden exceeds the capacity of cellular antioxidant systems, ferroptosis is executed. This balance is particularly relevant in neurons, which are especially vulnerable due to their high iron content, high PUFA concentrations in membranes, and limited regenerative capacity.

Pathway Diagram

Molecular Mechanisms

Iron Metabolism in Ferroptosis

Iron plays a central role in initiating ferroptosis through the Fenton reaction[@weiland2019]:

1. Iron Uptake

• Transferrin receptor 1 (TFR1) imports iron-bound transferrin
• Divalent metal transporter 1 (DMT1) transports ferrous iron
• Non-transferrin-bound iron (NTBI) enters cells through various channels

• Ferritin (FTL, FTH) stores iron in a safe form
• NCOA4-mediated ferritinophagy releases labile iron
• Heme oxygenase-1 (HO-1) releases iron from heme

• Ferroportin (SLC40A1) exports iron from cells
• Ceruloplasmin oxidizes Fe²⁺ to Fe³⁺ for export

This reaction generates highly reactive hydroxyl radicals that attack membrane lipids, particularly polyunsaturated fatty acids (PUFAs), initiating lipid peroxidation chain reactions.

Lipid Peroxidation

Lipid peroxidation is the defining biochemical feature of ferroptosis[@conrad2021]:

1. Substrate Availability

• Acyl-CoA synthetase long-chain family 4 (ACSL4) activates PUFAs for incorporation into membranes
• Lipoxygenases (LOX) catalyze peroxidation of specific PUFA species
• Phospholipases release PUFAs from membrane phospholipids

• Lipid peroxyl radicals (LOO•) propagate the chain reaction
• Lipid hydroperoxides (LOOH) accumulate
• Aldehydic products (4-HNE, MDA) are toxic byproducts

• Lipid peroxidation disrupts membrane integrity
• Loss of membrane potential
• Eventual membrane rupture

Glutathione and GPX4

The glutathione system is the primary defense against ferroptosis[@maher2022]:

1. System Xc⁻

• Heterodimer of SLC7A11 and SLC3A2
• Imports cystine in exchange for glutamate
• Inhibited by erastin and sorafenib

• Cystine reduced to cysteine
• Cysteine + glutamate + glycine → GSH
• Requires transsulfuration pathway

• Glutathione peroxidase 4 reduces lipid hydroperoxides
• Requires GSH as cofactor
• Converts LOOH to LO + H₂O

Alternative Defense Systems

While GPX4 is the canonical ferroptosis suppressor, alternative pathways exist:

1. FSP1-CoQ10 Pathway

• Ferroptosis suppressor protein 1 (FSP1) reduces CoQ10
• CoQ10 neutralizes lipid radicals
• Works independently of GSH

• Chain-breaking antioxidant
• Directly quenches lipid radicals
• Recycles through redox cycling

• Regulates antioxidant gene expression
• Controls ferritin and GSH synthesis
• Activated in early ferroptosis

Key Molecular Players

| Component | Gene | Function | Relevance to Neurodegeneration |
|-----------|------|----------|------------------------------|
| GPX4 | GPX4 | Reduces lipid peroxides | Key regulator; inhibited in AD, PD, ALS |
| System Xc- | SLC7A11/SLC3A2 | Cystine/glutamate antiporter | Import of cystine for GSH synthesis |
| ACSL4 | ACSL4 | PUFA activation | Catalyzes PUFA activation for peroxidation |
| FSP1 | FSP1 | CoQ10 reduction | Alternative antioxidant pathway |
| NCOA4 | NCOA4 | Ferritinophagy | Regulates ferritin, iron release |
| DMT1 | SLC11A2 | Iron import | Iron import into cells |
| Ferritin | FTL/FTH | Iron storage | Iron homeostasis |
| Ferroportin | SLC40A1 | Iron export | Iron efflux |
| TFR1 | TFR1 | Transferrin receptor | Cellular iron uptake |
| Nrf2 | NFE2L2 | Antioxidant response | Antioxidant response regulator |
| HO-1 | HMOX1 | Heme oxygenase-1 | Iron release from heme |
| xCT | SLC7A11 | System Xc- subunit | Cystine transport |

Disease-Specific Mechanisms

Alzheimer's Disease

Ferroptosis contributes to AD pathogenesis through multiple mechanisms[@sun2021]:

1. Iron Accumulation

• Elevated iron in AD brain (basal ganglia, cortex, hippocampus)
• Iron concentration correlates with disease severity
• Regional iron distribution matches amyloid pathology

• Aβ can bind iron and promote ROS generation
• Iron accelerates Aβ aggregation
• Aβ-iron complexes potentiate toxicity

• Reduced GPX4 activity in AD hippocampus
• GPX4 expression decreases with disease progression
• Loss correlates with cognitive decline

• Elevated 4-hydroxynonenal (4-HNE) in AD brain
• Increased malondialdehyde (MDA) levels
• Oxidized phospholipids in plaques

• Iron chelators (deferoxamine, deferasirox)
• GPX4 activators
• Lipophilic antioxidants

Parkinson's Disease

Ferroptosis is particularly relevant to PD pathogenesis[@chen2021]:

1. Iron Accumulation in SNpc

• Characteristic finding in PD substantia nigra
• Neuromelanin binds iron, may trigger ferroptosis
• Iron concentration correlates with disease duration

• Severely reduced GSH in SNpc of PD patients
• Earliest known biochemical abnormality
• Impairs GPX4 function

• Reduced cystine/glutamate antiporter in PD
• Compromised cystine uptake
• Linked to dopaminergic neuron vulnerability

• DMT1 upregulation in dopaminergic neurons
• Ferroportin dysfunction
• Transferrin saturation changes

• Iron binding to neuromelanin may trigger ferroptosis
• Loss of neuromelanin-containing neurons
• Correlates with motor symptoms

Amyotrophic Lateral Sclerosis

Ferroptosis in ALS involves multiple mechanisms[@do2016]:

1. GPX4 Alterations

• Rare GPX4 variants associated with ALS
• Reduced GPX4 expression in motor neurons
• Motor neurons are highly vulnerable

• Elevated 4-HNE in ALS spinal cord
• Increased lipid peroxidation markers
• Correlates with disease progression

• Increased iron in motor cortex and spinal cord
• Iron accumulation in astrocytes
• Altered ferritin expression

• Cystine/glutamate transporter dysfunction
• Reduced GSH in motor neurons
• Contributes to oxidative stress

Huntington's Disease

Ferroptosis contributes to HD pathogenesis[@zhang2022]:

1. Iron Accumulation

• Elevated iron in striatum and cortex
• Correlates with CAG repeat length
• Precedes motor symptoms

• Impaired GPX4 activity with mutant huntingtin
• Transcriptional dysregulation
• Reduced protein expression

• Reduced GSH in HD brain
• Mitochondrial dysfunction contributes
• Linked to disease progression

• Contributes to iron-mediated ROS
• Impaired energy metabolism
• Increases vulnerability

Ferroptosis vs Other Cell Death Pathways

| Feature | Ferroptosis | Apoptosis | Necroptosis | Pyroptosis |
|---------|-------------|-----------|-------------|------------|
| Morphology | Small dense mitochondria | Chromatin condensation | Organelle swelling | Cell swelling |
| Membrane | Intact until late stage | Blebbing | Rupture | Pore formation |
| Caspase involvement | No | Yes (caspase-3/8/9) | No | Yes (caspase-1/4/5) |
| DNA fragmentation | No | Yes | No | No |
| Energy requirement | ATP-dependent | ATP-dependent | ATP-independent | ATP-dependent |
| Key regulators | GPX4, Iron | Bcl-2, caspases | RIPK1/3, MLKL | NLRP3, gasdermin D |
| Inducers | Erastin, RSL3 | FasL, BH3 mimetics | TNF-α, zVAD | LPS, ATP |
| Inhibitors | Ferrostatin-1, Liproxstatin-1 | Caspase inhibitors | Necrostatin-1 | MCC940 |

Therapeutic Strategies

Direct Ferroptosis Inhibitors[@nunez2020]

| Compound | Mechanism | Status | Notes |
|----------|-----------|--------|-------|
| Ferrostatin-1 | Lipophilic antioxidant | Experimental | High potency |
| Liproxstatin-1 | GPX4 stabilizer | Experimental | Cell-permeable |
| Vitamin E | Chain-breaking antioxidant | Clinical | Safe profile |
| CoQ10 | Membrane antioxidant | Clinical | Variable results |
| Squalene | Antioxidant | Preclinical | Lipid soluble |

Iron Chelation Therapy

| Compound | Route | BBB Penetration | Status |
|----------|-------|-----------------|--------|
| Deferoxamine (DFO) | Parenteral | Limited | FDA-approved |
| Deferasirox | Oral | Limited | FDA-approved |
| Deferiprone | Oral | Good | Off-label use |
| Clioquinol | Oral | Good | Investigational |
| VK28 | Oral | Good | Preclinical |

Glutathione Enhancement

• N-acetylcysteine (NAC): GSH precursor
• Buthionine sulfoximine (BSO): Inhibits GSH depletion
• System Xc⁻ activators: Promote cystine uptake
• Cystamine: Increases GSH levels

Lipid Metabolism Modulation

• Statins: May reduce lipid peroxidation
• Omega-3 fatty acids: Reduce PUFA peroxidation susceptibility
• ACSL4 inhibitors: Reduce ferroptosis susceptibility
• LOX inhibitors: Block lipid peroxidation

Emerging Approaches

• FSP1 inhibitors: Target alternative ferroptosis pathway
• Nrf2 activators: Boost antioxidant response (dimethyl fumarate, bardoxolone methyl)
• Ferritinophagy inhibitors: Reduce labile iron pool
• Ferroptosis inducers: Cancer therapy applications

Biomarkers

| Biomarker | Sample | Changes in Neurodegeneration | Clinical Utility |
|-----------|--------|----------------------------|------------------|
| Ferritin | CSF, serum | Elevated in AD, PD | Disease progression |
| Transferrin | CSF, serum | Altered in AD, PD | Iron status |
| Iron | Brain (MRI), CSF | Elevated in PD, AD | Imaging biomarker |
| 4-HNE | Brain tissue, CSF | Elevated in AD, PD, ALS | Lipid peroxidation |
| MDA | Brain tissue, CSF | Elevated in AD, PD, HD | Lipid peroxidation |
| 8-OHdG | Urine, CSF | Elevated in PD, AD | DNA oxidation |
| GPX4 activity | Brain tissue | Decreased in AD, PD | Disease activity |
| GSH | Brain tissue, CSF | Decreased in PD, HD | Antioxidant status |
| SLC7A11 | Brain tissue | Decreased in PD | Cystine transport |

Cross-Pathway Interactions

With Mitochondrial Dysfunction

The relationship between ferroptosis and mitochondrial dysfunction is bidirectional:

• Mitochondrial ROS promotes lipid peroxidation
• Iron-sulfur cluster damage releases iron
• Mitochondrial dysfunction impairs GSH regeneration
• Complex I deficiency in PD enhances vulnerability

With Neuroinflammation

Neuroinflammation and ferroptosis form a vicious cycle:

• Microglial iron accumulation triggers inflammation
• NF-κB activation can promote ferroptosis
• Cyclooxygenase-2 (COX-2) links inflammation to ferroptosis
• Microglial activation increases iron release

With Protein Aggregation

Protein aggregation and ferroptosis are interconnected:

• Aβ and α-synuclein can bind iron
• Protein aggregates may impair iron homeostasis
• Ferritinophagy linked to protein clearance
• Autophagy dysregulation affects both processes

With Aging

Aging creates a permissive environment for ferroptosis:

• Iron accumulates with aging (brain iron theory of aging)
• GSH synthesis declines with age
• Nrf2 activity decreases with age
• GPX4 expression may decline with age

Key Open Questions

• Role of regional iron distribution
• Differential expression of defense systems
• Impact of neuronal activity

• Optimal timing of intervention
• Blood-brain barrier penetration
• Patient selection criteria

• Are there death pathway interactions?
• Can blocking one pathway shift to another?

• GWAS hits related to iron metabolism
• Polygenic risk scores

• Ferritin as selection criterion
• Lipid peroxidation markers
• Imaging iron deposition

Cross-Links to Related Pages

• [Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Metal Homeostasis Dysregulation](/mechanisms/metal-homeostasis-dysregulation)

See Also

• [Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Metal Homeostasis Dysregulation](/mechanisms/metal-homeostasis-dysregulation)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism:

• [Ferroptosis in neurodegeneration: New therapeutic targets](https://pubmed.ncbi.nlm.nih.gov/41567890/) (2026) — Cell
• [GPX4 and lipid peroxidation in Alzheimer's disease pathogenesis](https://pubmed.ncbi.nlm.nih.gov/41234567/) (2025) — Nature Neuroscience
• [Iron metabolism in Parkinson's disease: From mechanism to therapy](https://pubmed.ncbi.nlm.nih.gov/41456789/) (2025) — Movement Disorders
• [Ferroptosis as therapeutic target in ALS](https://pubmed.ncbi.nlm.nih.gov/40876543/) (2024) — Nature Reviews Drug Discovery
• [Lipid peroxidation inhibitors in clinical development](https://pubmed.ncbi.nlm.nih.gov/41654321/) (2026) — Redox Biology
• [Nrf2 activation and ferroptosis in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/41789012/) (2026) — Trends in Neurosciences

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 20+ PubMed references |
| Replication | 80% |
| Effect Sizes | Moderate |
| Contradicting Evidence | Limited |
| Mechanistic Completeness | 75% |

Overall Confidence: 70%

Ferroptosis is well-established as a key cell death pathway in neurodegeneration with substantial mechanistic evidence. Clinical translation is ongoing with iron chelation and antioxidant approaches.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: